Androgen Deficiency 10

Total Page:16

File Type:pdf, Size:1020Kb

Androgen Deficiency 10 Androgen Deficiency Contents At A Glance 04 Male Hormones 06 Androgen Deficiency 10 Symptoms 11 Causes 14 - DATE REVIEWED: JANUARY 2019 (6TH EDITION) © Healthy Male (Andrology Australia) 2003 Staying Healthy 20 Diagnosis 22 Health information in this booklet describes ANDROGEN DEFICIENCY. Diagnosis and treatment options are described to help men and their families understand the health problem, Treatment 29 make men aware of the available treatment options, and to help make talking with their doctor easier. Support 45 The information contained in this booklet is based on up-to- date medical evidence. It has been provided for educational purposes only. It is not intended to take the place of a clinical Glossary 48 diagnosis or medical advice from a fully qualified health professional. Healthy Male urges readers to seek the services of a qualified health professional for any personal health Expert Reviewers 51 concerns. Although the information in this booklet has been carefully reviewed, Healthy Male does not take any responsibility for any person using the information or advice available in this booklet. Information is given on the understanding that users take responsibility for checking the relevance and accuracy of the information. Healthy Male is supported by funding from the Australian Government Department of Health and is administered by Monash University. At A Glance What causes androgen problems in the testes or the deficiency? pituitary gland. Androgen deficiency happens when there are problems within the testes How is androgen deficiency or with hormone production in the treated? brain. This may be due to genetic What is testosterone? conditions or may occur as a result Androgen deficiency is treated of other medical problems affecting with testosterone therapy; this Testosterone is the major androgen (male sex hormone) the testes (e.g. infection, surgery) means giving testosterone in doses or pituitary (benign tumours and/ that return the testosterone levels in men and is needed for normal reproductive and or their treatment). A common in the blood to a normal range. sexual function. Testosterone is required for the physical chromosomal disorder that causes Testosterone is prescribed for men androgen deficiency is Klinefelter with androgen deficiency confirmed changes that happen during male puberty, such as syndrome. by blood tests. Once started, development of the penis and testes, and for the features testosterone therapy is usually continued for life and the man typical of adult men such as facial and body hair and a How is androgen deficiency needs to be monitored regularly by masculine physique. Testosterone also acts on cells in the diagnosed? a doctor. testes to make sperm. A diagnosis of androgen deficiency involves having a thorough medical Can I do anything to prevent evaluation and at least two blood androgen deficiency? Testosterone is also important for overall good health. samples (taken in the morning on There are no known ways to It helps the growth and maintenance of bones and different days) to measure hormone levels. Diagnosis should not be simply prevent androgen deficiency muscles, and affects mood and libido (sex drive). Some based on symptoms as these could caused by damage to the testes or pituitary gland. However, if your testosterone is changed into oestrogen, the female sex be caused by other health problems that need different treatment. low testosterone levels are caused hormone, as this is needed for bone health in men. by other illness, living a healthier In a man with clinical features of lifestyle and managing other androgen deficiency, the diagnosis health problems, may improve your What is androgen deficiency? What are the symptoms of is only confirmed when blood testosterone levels. Not all men have a drop in testosterone levels androgen deficiency? tests show a lower than normal Androgen, or testosterone, testosterone level and other blood with age. Those who maintain good deficiency occurs when the Symptoms of androgen deficiency tests show whether it is due to health as they age are more likely body is not able to make enough include low energy levels, to have normal testosterone levels. testosterone for the body to mood swings, irritability, poor function normally. Although not a concentration, reduced muscle life-threatening problem, androgen strength and low libido (sex drive). deficiency can affect your quality Symptoms often overlap with of life. those of other illnesses. Androgen deficiency has different symptoms depending on the age of the man. 04 05 Male Hormones Lumen Androgens are male What are hormones? Seminiferous tubule sex hormones that Developing sperm Hormones are chemical messengers made by increase at puberty glands in the body that are carried in the blood Supporting or and are needed for a to act on other organs in the body. Hormones are boy to develop into nurse cell (Sertoli cell) needed for growth, reproduction and well-being. a sexually mature Leydig cells adult who can reproduce What are androgens? Cross-sectionLumen of a testis showing sperm-producing tubes Androgens are male sex hormones that increase (seminiferousSeminiferous tubules) tubule and Leydig cells at puberty and are needed for a boy to develop into a sexually mature adult who can reproduce. Developing sperm The most important androgen is testosterone. WhereSupporting is testosterone or made? nurse cell (Sertoli cell) Testosterone is mainly made in the testes by What is testosterone? cells (theLeydig Leydig cells cells) that lie between the Testosterone is the major androgen (male sex small tubes that make sperm (the seminiferous hormone) in men and is needed for normal tubules). Testosterone is carried in the blood to a reproductive and sexual function. Testosterone number of different organs in the body including is required for the physical changes that happen the skin, hair and muscle. A small amount of during male puberty, such as development of the testosterone is also made by the adrenal glands, penis and testes, and for the features typical which are walnut-sized glands that sit on top of of adult men such as facial and body hair. the kidneys. Testosterone also acts on cells in the testes to make sperm. How do hormones control the testes? Testosterone is also important for overall good The pituitary gland and the hypothalamus, health. It helps the growth and maintenance of located at the base of the brain, control the bones and muscles, and affects mood and libido production of male hormones and sperm. (sex drive). Some testosterone is changed into The hypothalamus makes gonadotropin-releasing oestradiol, the female sex hormone, and this is hormone (GnRH), which controls the release of important for metabolism (physical and chemical other (messenger) hormones from the pituitary processes in the body) and bone health in men. gland. Luteinising hormone (LH) and follicle stimulating hormone (FSH) are the two important 06 07 Male Hormones messenger hormones made by the pituitary gland that act on the testes to make testosterone and sperm. Hypothalamus Pituitary What happens to testosterone in the Testis blood? As testosterone moves through the body in the Hypothalamus blood, it is converted into other sex hormones, Hormone links between the brain and the testes Pituitary ‘oestradiol’ and ‘dihydrotestosterone’ (DHT). Oestradiol (a type of oestrogen) is needed for How doesTestis ageing affect testosterone male bone health and prevents osteoporosis (thinning of the bones). DHT is a powerful levels? androgen that is made from testosterone in Testosterone levels in men are highest between some parts of the body, such as the skin and the the ages of 20 and 30 years. As men age there prostate. may be a small, gradual drop in testosterone levels; this could be by up to one third between 30 and 80 years of age. How do testosterone levels change over the day? This fall in testosterone is largely due to the effects of other conditions that men may develop Blood levels of testosterone change across as they age, such as obesity, diabetes and other the day. Testosterone levels are highest early chronic health disorders. On the other hand, in the morning and lowest late in the evening. healthy older men with normal body weight Testosterone levels may also be up to 10% higher usually do not experience a significant drop in when men are fasting. This pattern across the serum testosterone levels. day is called a ‘circadian rhythm’ and happens normally in many of the body’s hormonal systems. There is no such thing as ‘male menopause’ or There is no longer term cycle for men like the ‘andropause’ that can be compared to menopause monthly menstrual cycle for women. in women. Such terms have no medical meaning and are frequently used by those wishing to promote the use of testosterone in settings where there is no real evidence that it will help and where the risks are unknown. 08 09 Androdgen deficiency Symptoms Testosterone is the What is androgen (or testosterone) What are the symptoms of androgen Symptoms of most important deficiency? deficiency? androgen deficiency androgen (male sex include low energy hormone) in men Androgen, or testosterone, deficiency is when the Symptoms of androgen deficiency include low levels, mood swings, body is not able to make enough testosterone energy levels, mood swings, irritability, poor irritability, poor for the body to function normally. Although not concentration, reduced muscle strength and concentration, a life-threatening problem, androgen deficiency low libido (sex drive). Androgen deficiency has reduced muscle can affect your quality of life. different symptoms depending on the age of the strength and low man (Table). libido (sex drive) How common is androgen deficiency? Any of these symptoms on their own may not mean you have androgen deficiency. Many Androgen deficiency caused by problems in the illnesses can cause a drop in testosterone levels testes or hypothalamus-pituitary (glands in the and some of the symptoms of these illnesses are brain) affects about one in 200 men under 60 like the symptoms of androgen deficiency.
Recommended publications
  • Sex Hormones Related Ocular Dryness in Breast Cancer Women
    Journal of Clinical Medicine Review Sex Hormones Related Ocular Dryness in Breast Cancer Women Antonella Grasso 1, Antonio Di Zazzo 2,* , Giuseppe Giannaccare 3 , Jaemyoung Sung 4 , Takenori Inomata 4 , Kendrick Co Shih 5 , Alessandra Micera 6, Daniele Gaudenzi 2, Sara Spelta 2 , Maria Angela Romeo 7, Paolo Orsaria 1, Marco Coassin 2 and Vittorio Altomare 1 1 Breast Unit, University Campus Bio-Medico, 00128 Rome, Italy; [email protected] (A.G.); [email protected] (P.O.); [email protected] (V.A.) 2 Ophthalmology Operative Complex Unit, University Campus Bio-Medico, 00128 Rome, Italy; [email protected] (D.G.); [email protected] (S.S.); [email protected] (M.C.) 3 Department of Ophthalmology, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy; [email protected] 4 Department of Ophthalmology, School of Medicine, Juntendo University, 1130033 Tokyo, Japan; [email protected] (J.S.); [email protected] (T.I.) 5 Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong; [email protected] 6 Research and Development Laboratory for Biochemical, Molecular and Cellular Applications in Ophthalmological Sciences, IRCCS–Fondazione Bietti, 00198 Rome, Italy; [email protected] 7 School of Medicine, Humanitas University, 20089 Milan, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-06225418893; Fax: +39-9622541456 Abstract: Background: Dry eye syndrome (DES) is strictly connected to systemic and topical sex hor- mones. Breast cancer treatment, the subsequent hormonal therapy, the subsequent hyperandrogenism and the early sudden menopause, may be responsible for ocular surface system failure and its clinical Citation: Grasso, A.; Di Zazzo, A.; manifestation as dry eye disease.
    [Show full text]
  • Androgens Utilization Management Criteria
    ANDROGENS UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: Androgens Generic (Brand) NAMES: • Fluoxymesterone (Androxy®) • Methyltestosterone (Android®, Methitest®, Testred®) • Testosterone, topical A. Androderm®, Androgel® - Preferred topical testosterone ® ® ® ™ B. Testim , Fortesta , Axiron , Bio-T-Gel • Testosterone, buccal (Striant®) • Testosterone cypionate (e.g., Depo-Testosterone®) • Testosterone enanthate (e.g., Delatestryl®) FDA-APPROVED INDICATIONS: Replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. Hypogonadotropic hypogonadism (congenital or acquired): Idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty: To stimulate puberty in carefully selected males with clearly delayed puberty. Metastatic mammary cancer in women: Used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal COVERAGE AUTHORIZATION CRITERIA for the androgen products listed above: 1. Being used for ONE of the following: a. Males for the treatment of hypogonadism (low testosterone): i. patient has symptoms of androgen deficiency AND ii. has a baseline (pre-treatment) morning serum total testosterone level of less than or equal to 300 ng/dL or a serum total testosterone level that is below the testing laboratory’s lower limit of the normal range OR iii. baseline morning serum free testosterone level, measured by the equilibrium dialysis method, of less than or equal to 50 pg/ml or a free serum testosterone level that is below the testing laboratory’s lower limit of the normal range, OR b.
    [Show full text]
  • Serum Androgen Profiles in Women with Premature Ovarian Insufficiency: a Systematic Review and Meta-Analysis
    Menopause: The Journal of The North American Menopause Society Vol. 26, No. 1, pp. 78-93 DOI: 10.1097/GME.0000000000001161 ß 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The North American Menopause Society. Serum androgen profiles in women with premature ovarian insufficiency: a systematic review and meta-analysis Midhun Soman, MS,1 Li-Cong Huang, MD,1 Wen-Hui Cai, MS,1 Jun-Bi Xu, MS,1 Jun-Yao Chen, MD,1 Ren-Ke He, MS,1 Heng-Chao Ruan, MS,1,2,3 Xiang-Rong Xu, MD,1,2,3 Zhi-Da Qian, MD,1,2,3,4 and Xiao-Ming Zhu, MD, PhD1,2,3 Abstract Objective: This meta-analysis aims to investigate serum androgen profiles (testosterone, dehydroepiandroster- one sulfate, androstenedione, and sex hormone-binding globulin) in women with premature ovarian failure and to establish if there is evidence of diminished androgen levels in these women. Methods: Various Internet sources of PubMed, Cochrane library, and Medline were searched systematically until February, 2018. Out of a pool of 2,461 studies, after applying the inclusion/exclusion criterion, 14, 8, 10, and 9 studies were chosen for testosterone, dehydroepiandrosterone sulfate, androstenedione, and sex hormone-binding globulin, respectively, for this meta-analysis. The effect measure was the standardized mean difference with 95% confidence interval (95% CI) in a random-effects model. Results: The testosterone concentrations in premature ovarian insufficiency were compared with fertile controls: stamdard mean difference (IV, random, 95% CI) À0.73 [À0.99, À0.46], P value < 0.05. The dehydroepiandrosterone sulfate concentrations in premature ovarian insufficiency compared to fertile controls: standard mean difference (IV, random, 95% CI) À0.65 [À0.92, À0.37], P value < 0.05.
    [Show full text]
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’S Time to Sound the Alarm
    Review Article Health promotion, disease prevention, and lifestyle pISSN: 2287-4208 / eISSN: 2287-4690 World J Mens Health 2020 Jul 38(3): 323-337 https://doi.org/10.5534/wjmh.200012 Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’s Time to Sound the Alarm Abdulmaged M. Traish Department of Urology, Boston University School of Medicine, Boston, MA, USA 5α-dihydrotestosterone (5α-DHT) is the most potent natural androgen. 5α-DHT elicits a multitude of physiological actions, in a host of tissues, including prostate, seminal vesicles, hair follicles, skin, kidney, and lacrimal and meibomian glands. How- ever, the physiological role of 5α-DHT in human physiology, remains questionable and, at best, poorly appreciated. Recent emerging literature supports a role for 5α-DHT in the physiological function of liver, pancreatic β-cell function and survival, ocular function and prevention of dry eye disease and kidney physiological function. Thus, inhibition of 5α-reductases with finasteride or dutasteride to reduce 5α-DHT biosynthesis in the course of treatment of benign prostatic hyperplasia (BPH) or male pattern hair loss, known as androgenetic alopecia (AGA) my induces a novel form of tissue specific androgen deficien- cy and contributes to a host of pathophysiological conditions, that are yet to be fully recognized. Here, we advance the con- cept that blockade of 5α-reductases by finasteride or dutasteride in a mechanism-based, irreversible, inhabitation of 5α-DHT biosynthesis results in a novel state of androgen deficiency, independent of circulating testosterone levels. Finasteride and dutasteride are frequently prescribed for long-term treatment of lower urinary tract symptoms in men with BPH and in men with AGA.
    [Show full text]
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • Androgen Deficiency Guideline Results
    Improving testosterone testing in people living with HIV V. Kopanitsa1, S. Flavell2, J. Ashby2, I. Ghosh2, S. Candfield2, U. Srirangalingm2, L. Waters2 1. University College London (UCL) Medical School; 2. Central and North West London NHS Foundation Trust Introduction Aims Symptomatic testosterone (T) deficiency is more common in people living 1. Review local practice in the clinic with HIV (PLWH) than the HIV negative male population; despite this, 2. Introduce a local guideline with investigation and management pathways specific guidelines are lacking. [1,2] for assessing T deficiency in PLWH with a view to earlier diagnosis and more efficient use of resources Patients with T deficiency can experience a number of symptoms such as 3. Re-audit after guideline implementation erectile dysfunction (ED) and reduced libido, and also less specific symptoms including low mood, fatigue and reduced muscle mass [1,2,3]. Total T (free and protein-bound) is the most common measurement reported Methods when a testosterone test is requested. In PLWH, raised sex hormone 1. A retrospective notes review was completed on all patients who had a T binding globulin (SHBG) levels are common, and so calculation of free T test between 01/06/17 and 30/11/17, and 17/09/18 to 14/12/18, before more accurately reflects T levels in this group. SHBG and Albumin tests are and after guideline implementation, respectively. The following outcomes needed for this for this calculation, which is done via an online calculator [4]. from the guideline were assessed: T also varies by circadian rhythm and should be measured at peak time in 2.
    [Show full text]
  • Adverse Effects of Anabolic-Androgenic Steroids: a Literature Review
    healthcare Review Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review Giuseppe Davide Albano 1,†, Francesco Amico 1,†, Giuseppe Cocimano 1, Aldo Liberto 1, Francesca Maglietta 2, Massimiliano Esposito 1, Giuseppe Li Rosi 3, Nunzio Di Nunno 4, Monica Salerno 1,‡ and Angelo Montana 1,*,‡ 1 Legal Medicine, Department of Medical, Surgical and Advanced Technologies, “G.F. Ingrassia”, University of Catania, 95123 Catania, Italy; [email protected] (G.D.A.); [email protected] (F.A.); [email protected] (G.C.); [email protected] (A.L.); [email protected] (M.E.); [email protected] (M.S.) 2 Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; [email protected] 3 Department of Law, Criminology, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy; [email protected] 4 Department of History, Society and Studies on Humanity, University of Salento, 73100 Lecce, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-095-3782153 † These authors contributed equally to this work. ‡ These authors share last authorship. Abstract: Anabolic-androgenic steroids (AASs) are a large group of molecules including endoge- nously produced androgens, such as testosterone, as well as synthetically manufactured derivatives. AAS use is widespread due to their ability to improve muscle growth for aesthetic purposes and athletes’ performance, minimizing androgenic effects. AAS use is very popular and 1–3% of US inhabitants have been estimated to be AAS users. However, AASs have side effects, involving all organs, tissues and body functions, especially long-term toxicity involving the cardiovascular system Citation: Albano, G.D.; Amico, F.; and the reproductive system, thereby, their abuse is considered a public health issue.
    [Show full text]
  • Androgen Deficiency Diagnosis and Management
    4 Clinical Summary Guide Androgen Deficiency Diagnosis and management Androgen deficiency (AD) * Pituitary disease, thalassaemia, haemochromatosis. • Androgen deficiency is common, affecting 1 in 200 men under ** AD is an uncommon cause of ED. However, all men presenting 60 years with ED should be assessed for AD • The clinical presentation may be subtle and its diagnosis Examination and assessment of clinical features of AD overlooked unless actively considered Pre-pubertal onset – Infancy The GP’s role • Micropenis • GPs are typically the first point of contact for men with • Small testes symptoms of AD • The GP’s role in the management of AD includes clinical Peri-pubertal onset – Adolescence assessment, laboratory investigations, treatment, referral • Late/incomplete sexual and somatic maturation and follow-up • Small testes • Note that it in 2015 the PBS criteria for testosterone • Failure of enlargement of penis and skin of scrotum becoming prescribing changed; the patient must be referred for a thickened/pigmented consultation with an endocrinologist, urologist or member of • Failure of growth of the larynx the Australasian Chapter of Sexual Health Medicine to be eligible for PBS-subsidised testosterone prescriptions • Poor facial, body and pubic hair • Gynecomastia Androgen deficiency and the ageing male • Poor muscle development • Ageing may be associated with a 1% decline per year in serum Post-pubertal onset – Adult total testosterone starting in the late 30s • Regression of some features of virilisation • However, men who
    [Show full text]
  • Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and Is a Therapeutic Target for Advanced Prostate Cancer
    Author Manuscript Published OnlineFirst on September 14, 2020; DOI: 10.1158/1078-0432.CCR-20-1682 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Steroid sulfatase stimulates intracrine androgen synthesis and is a therapeutic target for advanced prostate cancer Cameron M. Armstrong1*, Chengfei Liu1*, Liangren Liu1,2*, Joy C. Yang1, Wei Lou1, Ruining Zhao1,3, Shu Ning1, Alan P. Lombard1, Jinge Zhao1, Leandro S D'Abronzo1, Christopher P. Evans1,4, Pui-Kai Li5, Allen C. Gao1, 4, 6,7 Running title: Targeting steroid sulfatase for advanced prostate cancer Key words: Prostate cancer, steroid sulfatase, resistance, intracrine androgen synthesis, adrenal androgens 1Department of Urologic Surgery, University of California Davis, CA, USA 2Present address: Department of Urology, West China Hospital, Sichuan University, China 3Present address: Department of Urology, General Hospital of Ningxia Medical University, China 4UC Davis Comprehensive Cancer Center, University of California Davis, CA, USA 5Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, USA 6VA Northern California Health Care System, Sacramento, CA, USA 7Corresponding author: Allen Gao, University of California Davis, 4645 2nd Avenue, Sacramento, CA 95817, USA. Phone: 916-734-8718, email: [email protected] *These authors contributed equally to the work. Conflict of interest: PKL and ACG are co-inventors of a patent application of the selected small molecule inhibitors of steroid sulfatase. 1 Downloaded from clincancerres.aacrjournals.org on October 1, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 14, 2020; DOI: 10.1158/1078-0432.CCR-20-1682 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Male Hypogonadism: Quick Reference for Residents
    Male hypogonadism: Quick Reference for Residents Soe Naing, MD, MRCP(UK), FACE Endocrinologist Associate Clinical Professor of Medicine Director of Division of Endocrinology Medical Director of Community Diabetes Care Center UCSF-Fresno Medical Education Program Version: SN/8-21-2017 Male hypogonadism From Harrison's Principles of Internal Medicine, 19e and Up-To-Date accessed on 8-21-2017 Testosterone is FDA-approved as replacement therapy only for men who have low testosterone levels due to disorders of the testicles, pituitary gland, or brain that cause hypogonadism. Examples of these disorders include primary hypogonadism because of genetic problems, or damage from chemotherapy or infection (mump orchitis). However, FDA has become aware that testosterone is being used extensively in attempts to relieve symptoms in men who have low testosterone for no apparent reason other than aging. Some studies reported an increased risk of heart attack, stroke, or death associated with testosterone treatment, while others did not. FDA cautions that prescription testosterone products are approved only for men who have low testosterone levels caused by a medical condition. http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm 2 Hypothalamic-pituitary-testicular axis Schematic representation of the hypothalamic-pituitary- testicular axis. GnRH from the hypothalamus stimulates the gonadotroph cells of the pituitary to secrete LH and FSH. LH stimulates the Leydig cells of the testes to secrete testosterone. The high concentration of testosterone within the testes is essential for spermatogenesis within the seminiferous tubules. FSH stimulates the Sertoli cells within the seminiferous tubules to make inhibin B, which also stimulates spermatogenesis. Testosterone inhibits GnRH secretion, and inhibin B inhibits FSH secretion.
    [Show full text]
  • Management of Women with Premature Ovarian Insufficiency
    Management of women with premature ovarian insufficiency Guideline of the European Society of Human Reproduction and Embryology POI Guideline Development Group December 2015 1 Disclaimer The European Society of Human Reproduction and Embryology (hereinafter referred to as 'ESHRE') developed the current clinical practice guideline, to provide clinical recommendations to improve the quality of healthcare delivery within the European field of human reproduction and embryology. This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. The aim of clinical practice guidelines is to aid healthcare professionals in everyday clinical decisions about appropriate and effective care of their patients. However, adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not override the healthcare professional's clinical judgment in diagnosis and treatment of particular patients. Ultimately, healthcare professionals must make their own clinical decisions on a case-by-case basis, using their clinical judgment, knowledge, and expertise, and taking into account the condition, circumstances, and wishes of the individual patient, in consultation with that patient and/or the guardian or carer. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. ESHRE shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein.
    [Show full text]